1-19 of 19
Heikki Joensuu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, Annette Reichardt, Kirsten Sundby Hall, Jochen Schütte, Silke Cameron, Peter Hohenberger, Harri Sihto, Philipp J. Jost, Lars H. Lindner, Sebastian Bauer, Bengt Nilsson, Raija Kallio, Tommi Pesonen, Peter Reichardt
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3313–3319.
https://doi.org/10.1158/1078-0432.CCR-22-3980
Published: 01 September 2023
View article titled, <em>KIT</em> and <em>PDGFRA</em> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
Open the PDF for <em>KIT</em> and <em>PDGFRA</em> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

Bruno Vincenzi, Andrea Napolitano, Marta Fiocco, Olivier Mir, Piotr Rutkowski, Jean-Yves Blay, Peter Reichardt, Heikki Joensuu, Elena Fumagalli, Spyridon Gennatas, Nadia Hindi, Margherita Nannini, Mariella Spalato Ceruso, Antoine Italiano, Giovanni Grignani, Antonella Brunello, Silvia Gasperoni, Tommaso De Pas, Giuseppe Badalamenti, Maria A. Pantaleo, Winan J. van Houdt, Nikki S. IJzerman, Neeltje Steeghs, Hans Gelderblom, Ingrid M.E. Desar, Johanna Falkenhorst, Marianna Silletta, Marta Sbaraglia, Giuseppe Tonini, Javier Martin-Broto, Peter Hohenberger, Axel Le Cesne, Robin L. Jones, Angelo P. Dei Tos, Alessandro Gronchi, Sebastian Bauer, Paolo G. Casali
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1672–1679.
https://doi.org/10.1158/1078-0432.CCR-21-1665
Published: 14 April 2022
View article titled, Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Open the PDF for Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial

Karama Asleh, Heather Ann Brauer, Amy Sullivan, Susanna Lauttia, Henrik Lindman, Torsten O. Nielsen, Heikki Joensuu, E. Aubrey Thompson, Saranya Chumsri
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2603–2614.
https://doi.org/10.1158/1078-0432.CCR-19-1945
Published: 01 June 2020
View article titled, Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial
Open the PDF for Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Anagrelide for Gastrointestinal Stromal Tumor

Olli-Pekka Pulkka, Yemarshet K. Gebreyohannes, Agnieszka Wozniak, John-Patrick Mpindi, Olli Tynninen, Katherine Icay, Alejandra Cervera, Salla Keskitalo, Astrid Murumägi, Evgeny Kulesskiy, Maria Laaksonen, Krister Wennerberg, Markku Varjosalo, Pirjo Laakkonen, Rainer Lehtonen, Sampsa Hautaniemi, Olli Kallioniemi, Patrick Schöffski, Harri Sihto, Heikki Joensuu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (5): 1676–1687.
https://doi.org/10.1158/1078-0432.CCR-18-0815
Published: 01 March 2019
View article titled, Anagrelide for Gastrointestinal Stromal Tumor
Open the PDF for Anagrelide for Gastrointestinal Stromal Tumor in another window
Includes: Supplementary data
Journal Articles

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1434.
https://doi.org/10.1158/1078-0432.CCR-18-4267
Published: 15 February 2019
View article titled, Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Journal Articles

p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial

Jeff Sperinde, Weidong Huang, Aki Vehtari, Ahmed Chenna, Pirkko-Liisa Kellokumpu-Lehtinen, John Winslow, Petri Bono, Yolanda S. Lie, Christos J. Petropoulos, Jodi Weidler, Heikki Joensuu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (13): 3046–3052.
https://doi.org/10.1158/1078-0432.CCR-17-3250
Published: 01 July 2018
View article titled, p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial
Open the PDF for p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial in another window
Includes: Supplementary data
Journal Articles

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4323–4334.
https://doi.org/10.1158/1078-0432.CCR-16-2287
Published: 01 August 2017
View article titled, HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Includes: Supplementary data
Journal Articles

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

Katrien Berns, Amir Sonnenblick, Annemiek Gennissen, Sylvain Brohée, E. Marielle Hijmans, Bastiaan Evers, Debora Fumagalli, Christine Desmedt, Sibylle Loibl, Carsten Denkert, Patrick Neven, Wei Guo, Fan Zhang, Theo A. Knijnenburg, Tjalling Bosse, Michiel S. van der Heijden, Sanne Hindriksen, Wouter Nijkamp, Lodewyk F.A. Wessels, Heikki Joensuu, Gordon B. Mills, Roderick L. Beijersbergen, Christos Sotiriou, René Bernards
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5238–5248.
https://doi.org/10.1158/1078-0432.CCR-15-2996
Published: 31 October 2016
View article titled, Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Open the PDF for Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance in another window
Includes: Supplementary data
Journal Articles

Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study

Harri Sihto, Tom Böhling, Heli Kavola, Virve Koljonen, Marko Salmi, Sirpa Jalkanen, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2872–2881.
https://doi.org/10.1158/1078-0432.CCR-11-3020
Published: 14 May 2012
View article titled, Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Open the PDF for Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study in another window
Includes: Supplementary data
Journal Articles

Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinoma

Harri Sihto, Heli Kukko, Virve Koljonen, Risto Sankila, Tom Böhling, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4806–4813.
https://doi.org/10.1158/1078-0432.CCR-10-3363
Published: 17 July 2011
View article titled, Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinoma
Open the PDF for Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance

Jonna Nevo, Elina Mattila, Teijo Pellinen, Daniel L. Yamamoto, Henri Sara, Kristiina Iljin, Olli Kallioniemi, Petri Bono, Päivi Heikkilä, Heikki Joensuu, Anni Wärri, Johanna Ivaska
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6570–6581.
https://doi.org/10.1158/1078-0432.CCR-09-0773
Published: 02 November 2009
View article titled, Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance
Open the PDF for Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance in another window
Includes: Supplementary data
Journal Articles

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Harri Sihto, Johan Lundin, Tiina Lehtimäki, Maarit Sarlomo-Rikala, Ralf Bützow, Kaija Holli, Liisa Sailas, Vesa Kataja, Mikael Lundin, Taina Turpeenniemi-Hujanen, Jorma Isola, Päivi Heikkilä, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (13): 4103–4110.
https://doi.org/10.1158/1078-0432.CCR-07-5003
Published: 01 July 2008
View article titled, Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening
Open the PDF for Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening in another window
Includes: Supplementary data
Journal Articles

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Michael C. Heinrich, Heikki Joensuu, George D. Demetri, Christopher L. Corless, Jane Apperley, Jonathan A. Fletcher, Denis Soulieres, Stephan Dirnhofer, Amy Harlow, Ajia Town, Arin McKinley, Shane G. Supple, John Seymour, Lilla Di Scala, Allan van Oosterom, Richard Herrmann, Zariana Nikolova, and Grant McArthur, for the Imatinib Target Exploration Consortium Study B2225
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2717–2725.
https://doi.org/10.1158/1078-0432.CCR-07-4575
Published: 01 May 2008
View article titled, Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases
Open the PDF for Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases in another window
Journal Articles

Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer

Nina Linder, Johan Lundin, Jorma Isola, Mikael Lundin, Kari O. Raivio, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (12): 4372–4381.
https://doi.org/10.1158/1078-0432.CCR-04-2280
Published: 15 June 2005
View article titled, Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer
Open the PDF for Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer in another window
Journal Articles

High LYVE-1–Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer

Petri Bono, Veli-Matti Wasenius, Päivi Heikkilä, Johan Lundin, David G. Jackson, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7144–7149.
https://doi.org/10.1158/1078-0432.CCR-03-0826
Published: 08 November 2004
View article titled, High LYVE-1–Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer
Open the PDF for High LYVE-1–Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer in another window
Journal Articles

Amplification of erbB2 and erbB2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0 Breast Cancer: A Nationwide Population-based Study

Heikki Joensuu, Jorma Isola, Mikael Lundin, Tiina Salminen, Kaija Holli, Vesa Kataja, Liisa Pylkkänen, Taina Turpeenniemi-Hujanen, Karl von Smitten, Johan Lundin
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 923–930.
Published: 01 March 2003
View article titled, Amplification of <em>erbB2</em> and erbB2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0 Breast Cancer: <subtitle>A Nationwide Population-based Study</subtitle>
Open the PDF for Amplification of <em>erbB2</em> and erbB2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0 Breast Cancer: <subtitle>A Nationwide Population-based Study</subtitle> in another window
Journal Articles

Hepatocyte Growth Factor Receptor , Matrix Metalloproteinase-11 , Tissue Inhibitor of Metalloproteinase-1 , and Fibronectin Are Up-Regulated in Papillary Thyroid Carcinoma: A cDNA and Tissue Microarray Study

Veli-Matti Wasenius, Samuli Hemmer, Eeva Kettunen, Sakari Knuutila, Kaarle Franssila, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 68–75.
Published: 01 January 2003
View article titled, <em>Hepatocyte Growth Factor Receptor</em> , <em>Matrix Metalloproteinase-11</em> , <em>Tissue Inhibitor of Metalloproteinase-1</em> , and <em>Fibronectin</em> Are Up-Regulated in Papillary Thyroid Carcinoma: <subtitle>A cDNA and Tissue Microarray Study</subtitle>
Open the PDF for <em>Hepatocyte Growth Factor Receptor</em> , <em>Matrix Metalloproteinase-11</em> , <em>Tissue Inhibitor of Metalloproteinase-1</em> , and <em>Fibronectin</em> Are Up-Regulated in Papillary Thyroid Carcinoma: <subtitle>A cDNA and Tissue Microarray Study</subtitle> in another window
Journal Articles

Interferon α-2a Therapy in 18 Hemangioblastomas

Mika Niemelä, Hanna Mäenpää, Petri Salven, Paula Summanen, Kristiina Poussa, Leila Laatikainen, Juha Jääskeläinen, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (3): 510–516.
Published: 01 March 2001
View article titled, Interferon α-2a Therapy in 18 Hemangioblastomas
Open the PDF for Interferon α-2a Therapy in 18 Hemangioblastomas in another window
Journal Articles

Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor

Petri Salven, Arto Orpana, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (3): 487–491.
Published: 01 March 1999
View article titled, Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor
Open the PDF for Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor in another window